Showing 71-80 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Enhancing Functional Maturation of Stem Cell-Derived Beta Cells Using Harmine for Improved Diabetes Therapy | Icahn School of Medicine at Mount Sinai | Peng Wang | Cures | 01-July-2025 to 30-June-2026 | $305,000.00 |
| Exploring the Effects of Beta Cell Regenerative Drugs on Cell Fate Decisions in Human Pancreatic Islets | Icahn School of Medicine at Mount Sinai | Esra Karakose | Cures | 01-March-2025 to 28-February-2030 | $999,999.00 |
| The KQ1 serum study: amendment & extension | Icahn School of Medicine at Mount Sinai | Dirk Homann | Cures | 01-November-2024 to 31-October-2027 | $1,873,290.24 |
| Bringing Beta Cell Regenerative Therapy to the Clinic | Icahn School of Medicine at Mount Sinai | Andrew Stewart | Cures | 01-January-2024 to 31-December-2026 | $1,000,000.00 |
| Exploiting SDF2L1 to protect against beta cell death and dysfunction in T1D | Indiana Biosciences Research Institute | Michael Kalwat | Cures | 01-December-2024 to 30-November-2027 | $748,169.00 |
| Targeting ER cargo proteins for beta cell protection against cellular stress and autoimmunity | Indiana Biosciences Research Institute | Erica Cai | Cures | 01-September-2023 to 31-August-2026 | $499,934.12 |
| ROLE OF ZBED3 IN BETA CELL STRESS RESPONSE AND VULNERABILITY AGAINST AUTOIMMUNITY | Indiana Biosciences Research Institute | Erica Cai | Cures | 01-March-2023 to 29-February-2028 | $999,737.71 |
| Clinical Translation of T-1123, an Ultra-rapid, Concentrated, Temperature stable Novel Insulin Analog | Invictus Therapeutics, LLC | Robyn Day | Improving Lives | 15-October-2025 to 31-May-2027 | $1,437,112.00 |
| JDRF-IQVIA Adult T1D Detection | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-October-2022 to 31-May-2026 | $953,780.00 |
| Advancing T1D Detection and Care Through AI | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-February-2025 to 31-May-2026 | $345,083.00 |